Stock Scorecard
Stock Summary for Kezar Life Sciences Inc (KZR) - $6.24 as of 12/3/2025 8:29:26 PM EST
Total Score
13 out of 30
Safety Score
29 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KZR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KZR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KZR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for KZR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for KZR (29 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 8 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 1 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for KZR
Company Overview |
|
|---|---|
| Ticker | KZR |
| Company Name | Kezar Life Sciences Inc |
| Country | USA |
| Description | Kezar Life Sciences, Inc. is an innovative clinical-stage biotechnology firm based in South San Francisco, California, specializing in the advancement of small molecule therapies aimed at immune-mediated diseases and cancer. By harnessing its proprietary drug discovery platform, the company is dedicated to meeting urgent medical needs, with a robust and varied pipeline of candidates currently undergoing clinical evaluation. Kezar's strategic emphasis on addressing complex therapeutic challenges positions it as a frontrunner in the biopharmaceutical landscape, with the potential to significantly enhance patient outcomes and transform treatment paradigms in pivotal disease areas. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 6.24 |
| Price 4 Years Ago | 167.20 |
| Last Day Price Updated | 12/3/2025 8:29:26 PM EST |
| Last Day Volume | 25,814 |
| Average Daily Volume | 69,073 |
| 52-Week High | 7.39 |
| 52-Week Low | 3.53 |
| Last Price to 52 Week Low | 76.77% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.11 |
| Sector PE | 88.06 |
| 5-Year Average PE | -48.11 |
| Free Cash Flow Ratio | 1.17 |
| Industry Free Cash Flow Ratio | 13.81 |
| Sector Free Cash Flow Ratio | 28.78 |
| Current Ratio Most Recent Quarter | 7.06 |
| Total Cash Per Share | 5.32 |
| Book Value Per Share Most Recent Quarter | 11.33 |
| Price to Book Ratio | 0.55 |
| Industry Price to Book Ratio | 33.69 |
| Sector Price to Book Ratio | 33.12 |
| Price to Sales Ratio Twelve Trailing Months | 6.03 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.75 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.97 |
| Analyst Buy Ratings | 0 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 7,323,200 |
| Market Capitalization | 45,696,768 |
| Institutional Ownership | 57.45% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 17.80% |
| Reported EPS 12 Trailing Months | -8.44 |
| Reported EPS Past Year | -5.40 |
| Reported EPS Prior Year | -6.35 |
| Net Income Twelve Trailing Months | -61,705,000 |
| Net Income Past Year | -83,736,000 |
| Net Income Prior Year | -101,870,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 38,935,000 |
| Total Cash Past Year | 41,749,000 |
| Total Cash Prior Year | 35,493,000 |
| Net Cash Position Most Recent Quarter | 37,561,000 |
| Net Cash Position Past Year | 36,638,000 |
| Long Term Debt Past Year | 5,111,000 |
| Long Term Debt Prior Year | 10,069,000 |
| Total Debt Most Recent Quarter | 1,374,000 |
| Equity to Debt Ratio Past Year | 0.96 |
| Equity to Debt Ratio Most Recent Quarter | 0.98 |
| Total Stockholder Equity Past Year | 116,916,000 |
| Total Stockholder Equity Prior Year | 187,570,000 |
| Total Stockholder Equity Most Recent Quarter | 82,976,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -56,659,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -7.74 |
| Free Cash Flow Past Year | -74,241,000 |
| Free Cash Flow Prior Year | -83,455,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.20 |
| MACD Signal | 0.26 |
| 20-Day Bollinger Lower Band | 2.69 |
| 20-Day Bollinger Middle Band | 4.88 |
| 20-Day Bollinger Upper Band | 7.06 |
| Beta | 0.51 |
| RSI | 61.03 |
| 50-Day SMA | 5.05 |
| 150-Day SMA | 12.71 |
| 200-Day SMA | 33.49 |
System |
|
| Modified | 12/2/2025 2:50:15 AM EST |